Phase I/Ib Study of Adoptive Cellular Therapy Using Autologous IL-21-Primed CD8+ Tumor Antigen-Specific T Cells in Combination With Utomilumab (PF-05082566) in Patients With Platinum Resistant Ovarian Cancer
Phase of Trial: Phase I
Latest Information Update: 31 Jan 2019
At a glance
- Drugs Utomilumab (Primary) ; Cyclophosphamide; Interleukin-2
- Indications Ovarian cancer
- Focus Adverse reactions; Therapeutic Use
- 03 Oct 2018 Planned End Date changed from 1 Jul 2021 to 1 Jul 2020.
- 31 Aug 2018 Biomarkers information updated
- 16 Jul 2018 Status changed from not yet recruiting to recruiting.